Qualitative evaluation of the Canadian Fabry disease initiative

Canadian Pharmacists Journal

Volumn 145, Issue 3, 2012, Pages 136-141

  Embrett, Mark ^a   MacKinnon, Neil J ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATTITUDE TO ILLNESS; CANADA; FABRY DISEASE; HUMAN; INTERVIEW; MEDICAL SPECIALIST; QUALITATIVE RESEARCH; REFERENCE DATABASE; REIMBURSEMENT;

EID: 84861364393     PISSN: 17151635     EISSN: 1913701X     Source Type: Journal    
DOI: 10.3821/145.3.cpj136     Document Type: Article

References (24)

1. Ramaswami U. Update on role of agalsidase alfa in management of Fabry disease. Drug Design Devel Ther 2011;12:155-73.
2. Alfadhel M, Sirrs S. Enzyme replacement therapy for Fabry disease: some answers but more questions. Ther Clin Risk Manag 2011;23:69-82.
3. Canadian Coordinating Office for Health Technology Assessment. CEDAX final recommendation and reasons for recommendation: agalsidase beta resubmission. 2005. Available: www.cadth.ca/media/cdr/complete/cdr_complete_Fabrazyme_Resubmission_may2005.pdf (accessed Oct. 12, 2010).
4. Bichet D, Casey R, Clarke J, et al. Canadian Fabry Disease Initiative annual report October 1, 2006 - November 30, 2007. 2008. Available: www.cihr-irsc.gc.ca/e/36618.html (accessed Oct. 12, 2010).
5. Canadian Institutes of Health Research. Canadian Fabry Disease Initiative study: scientific oversight. 2010. Available: www.cihr-irsc.gc.ca/e/35799.html (accessed Oct. 12, 2010).
6. ClinicalTrials.gov. Canadian Fabry Disease Initiative (CFDI) enzyme replacement therapy (ERT) study. Available: http://clinicaltrials.gov/ct2/show/NCT00455104 (accessed Nov. 28, 2011).
7. Sirrs S, Clarke JTR, Bichet DG, et al. Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative. Mol Genet Metab 2010;99:367-73.
8. Clarke LA, Clarke JTR, Sirrs S, et al. Fabry disease: recommendations for diagnosis, management and enzyme replacement therapy in Canada. Garrod Association. Available: www.garrod.ca/data/060613-1322-01.html(accessed Oct. 12, 2010).
9. Sofaer S. Qualitative methods: what are they and why use them? Health Serv Res 1999;34:1101-18.
10. Gilchrist VJ, Wlliams RL. Key informant interviews. In: Crabtree BF, Miller WL, editors. Doing qualitative research. 2nd ed. Thousand Oaks (CA): Sage Publications; 1999. p 71-88.
11. Patton MQ. Qualitative research and evaluation methods. Thousand Oaks (CA): Sage Publications; 2002.
12. Greene J. Qualitative program evaluation. In: Denzin NK,Lincoln YS, editors. Handbook of qualitative research. London (UK): Sage; 1994:530-44.
13. Pope C, Ziebland S, Mays N. Qualitative research in health care: analysing qualitative data. BMJ 2000;320:114-6.
14. Crabtree BF, Miller WL. The dance of interpretation. In Crabtree BF, Miller WL, editors. Doing qualitative research. Second edition. Thousand Oaks (CA): Sage Publications, Inc.; 1999. p 127-43.
15. Allen G. A critique of using grounded theory as a research method. Electron J Bus. Res Methods 2003;2:1-10.
16. Huberman A, Miles M. Data management and analysis methods. In: Denzin NK, Lincoln YS, editors. Handbook of qualitative research. London (UK): Sage; 1994:428-44.
17. Bereska T. The changing boys' world in the 20th century: reality and "fiction." J Mens Stud 2003;11:157-74.
18. Politz D, Beck C. Nursing research principles and methods. 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2004.
19. Côté AM, Durand MJ, Tousignant M, Poitras S. Physiotherapists and the use of low back pain guidelines: a qualitative study of the barriers and facilitators. J Occup Rehabil 2009;19:94-105.
20. Hopkin R, Bissler J, Banikazemi M, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 2008;64:550-5.
21. Band PR. The making of the Canadian Cancer Registry: cancer incidence in Canada and its regions, 1969 to 1988. Ottawa (ON): Canadian Council of Cancer Registries, Health and Welfare Canada, Statistics Canada; 1993.
22. Ellison LF. An empirical evaluation of period survival analysis using data from the Canadian Cancer Registry. Ann Epidemiol 2006;16:191-6.
23. Clarke J. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. CMAJ 2006;174:189-90.
24. MacKinnon NJ. Provincial drug plans: now there's a minefield. Can Pharm J 2004;137:14-6.